Meeting Banner
Abstract #3055

Tumor-targeted alkylphosphocholine chelates for dual-modality PET/MR imaging

Ray R Zhang1, Christinna L Brunnquell1, Reinier Hernandez1, Alan McMillan1, Anatoly N Pinchuk1, Paul A Clark2, Vincent L Cryns3, John S Kuo2, and Jamey P Weichert1

1Department of Radiology, University of Wisconsin Madison, Madison, WI, United States, 2Department of Neurological Surgery, University of Wisconsin Madison, Madison, WI, United States, 3Department of Medicine - Endocrinology, University of Wisconsin Madison, Madison, WI, United States

Extensive structure-activity relationships studies have previously shown that alkylphosphocholine (APC) analogs selectively deliver radioiodine and larger fluorophores to a variety of tumor types in rodent models and humans1-3. To further explore the payload capacity of APCs, we synthesized several new APC-chelates and assessed their ability to deliver Gd (MRI) and 64Cu (PET) selectively to tumors in vivo. Prolonged T1-weighted signal enhancement following Gd-DOTA-APC injection was observed in all tumor models. Clinical PET/MR imaging of U87 flank xenograft at 24h and 48h post-administration of Gd-DOTA-APC and 64Cu-DOTA-APC demonstrated co-localization of T1-weighted signal enhancement and PET activity in the tumor.

This abstract and the presentation materials are available to members only; a login is required.

Join Here